Exploiting 
the conformational 
complexity of GPCRs 
to innovate 
drug discovery​

Confo Therapeutics employs its proprietary CONFO® technology to lock inherently unstable functional conformations of GPCRs as a superior starting point for drug discovery. Confobody-stabilized active state conformations of these receptors reveal previously inaccessible structural features empowering the discovery of novel pathway-selective agonists for improved therapeutic intervention.​

About
Confo Therapeutics​

Confo Therapeutics is a drug discovery company building a unique pipeline of GPCR targeted therapeutics addressing unmet medical need.​

Conformational challenges of GPCR drug discovery​

Understanding the CONFO® technology​

CONFO® body-

enabled drug

discovery​

Distinguishing features

References

News

CEO appointment​

07.09.2016 

New CSO dr. Christel Menet

 10.05.2016

Financial closing

02.02.2016 

Pleinlaan 2
Building E, 7th Floor, Room E7.6
1050 Brussels, Belgium

info@confotherapeutics.com

Career

Opportunities

To join our talented team and become a part of our future success, please contact us​

Investors

Founding Institutes

Research

and development

 

Company incorporation

24.06.2015 

Confo Therapeutics to appoint Chairman

15.12.2016